In a groundbreaking advance toward understanding the molecular underpinnings of myelodysplastic syndromes (MDS), researchers have generated the first base-resolution DNA methylome from hematopoietic stem cells (HSCs) of human MDS patients. This landmark study, published in the prestigious journal Immunity & Inflammation, uncovers how epigenetic dysregulation—particularly involving the TET2-GFI1 axis—shapes the initiation and progression of MDS at the stem cell level. This work not only illuminates the pathophysiology of MDS but also opens new avenues for targeted therapeutic interventions aimed at reversing aberrant epigenetic states in malignant HSCs.
Myelodysplastic syndromes represent a heterogeneous group of clonal hematopoietic disorders marked by ineffective hematopoiesis and a predisposition for leukemic transformation. While previous studies have established that mutations in epigenetic regulators such as TET2 are prevalent in MDS, the precise molecular cascades through which these mutations affect DNA methylation landscapes and dysregulate gene expression in primitive HSCs remained elusive. By employing cutting-edge single-base resolution sequencing technology, the authors systematically mapped the DNA methylome of purified HSCs from high-risk MDS patients compared to healthy donors, providing an unprecedentedly comprehensive view of epigenetic remodeling in disease.
The results exposed a striking dichotomy in methylation patterns within MDS HSCs. CpG islands, typically involved in gene promoter regulation, exhibited widespread hypermethylation, which is known to enforce gene silencing. In stark contrast, repetitive genomic elements such as Alu sequences underwent significant hypomethylation, reflecting genome instability commonly observed in malignant states. This dual pattern disrupts the epigenetic equilibrium critical for maintaining HSC function and genomic integrity, corroborating the hypothesis that epigenomic instability is central to MDS pathogenesis.
Delving deeper into the functional impact of these alterations, the study identified differentially methylated regions linked to genes governing cancer-related biological pathways, extrinsic signaling cascades, and intrinsic transcriptional networks indispensable for HSC homeostasis. Prominently, the transcriptional regulator GFI1 was found to harbor a hypermethylated promoter region concomitant with suppressed gene expression, while the proto-oncogene BMI1 displayed hypomethylation correlated with its upregulation. These epigenetic modifications perturb the tightly regulated balance of proliferation and differentiation in HSCs, priming them for malignant transformation.
Central to this epigenetic disruption is TET2, a dioxygenase that catalyzes iterative oxidation of 5-methylcytosine to 5-hydroxymethylcytosine and further intermediates, thereby facilitating active DNA demethylation. Frequently mutated in MDS and myeloid malignancies, TET2’s functional role in safeguarding HSC epigenomic landscapes is now elucidated with greater clarity. Utilizing both MDS mouse models and Tet2 knockout mice, the investigators demonstrated that TET2 directly mediates demethylation at the Gfi1 promoter. Absence of Tet2 precipitates hypermethylation and silencing of Gfi1, disrupting normal transcriptional repression necessary to restrain HSC expansion.
The consequences of TET2 loss were elucidated through mechanistic interrogation in aged Tet2-deficient mice, which develop an MDS-like phenotype mirroring human disease. Here, the TET2-GFI1 axis emerged as a critical epigenetic brake that limits pathological HSC proliferation, thereby suppressing malignant evolution. This insight connects aging-associated stem cell dysregulation, a known risk factor for hematological malignancies, with specific epigenetic aberrations triggered by TET2 dysfunction, providing a conceptual framework linking stem cell aging and cancer initiation.
Beyond fundamental biology, these findings carry profound therapeutic implications. High-risk MDS HSCs display global DNA hypermethylation alongside regional hypomethylation, suggesting that pharmacologic agents modulating DNA methylation patterns could restore epigenomic balance. Specifically, targeting DNA methylation at the GFI1 locus or its downstream pathways may reverse transcriptional repression and normalize HSC function. Given the prevalent occurrence of TET2 mutations in MDS, therapeutic strategies aimed at correcting aberrant methylation in this epigenetic axis hold promise for precision medicine approaches.
Importantly, this work transcends previous studies limited by low-resolution methylation analyses or candidate gene focus, instead harnessing single-base resolution technology to construct a panoramic and nuanced methylation landscape. By integrating human patient data with sophisticated genetic animal models, the study bridges clinical observations with molecular mechanisms, establishing a pathogenic cascade from epigenetic enzyme mutations to methylome disruption and aberrant transcription factor regulation.
The elucidation of the TET2-GFI1 axis as a pivotal protective mechanism in HSCs underscores the dynamic nature of epigenetic regulation governing stem cell homeostasis and malignant progression. This conceptual advance prompts reconsideration of disease initiation models in MDS, emphasizing the importance of epigenetic “brakes” in preserving stem cell integrity amid oncogenic insults.
As the field moves toward epigenetic therapies, this research offers an essential roadmap for designing combination regimens, such as pairing DNA hypomethylating agents with precise modulators of transcription factor activity. Such strategies may yield improved clinical responses in high-risk MDS patients, particularly those harboring TET2 mutations, by addressing both global methylome abnormalities and locus-specific dysregulation.
The study’s comprehensive approach—combining patient-derived primary HSC methylomes with functional validation in animal models—exemplifies a translational paradigm for dissecting cancer epigenetics. Future endeavors building on this foundation will likely explore the broader epigenetic landscape and its interplay with chromatin modifiers, transcriptional machinery, and microenvironmental cues impacting HSC pathology.
In conclusion, the generation of a base-resolution DNA methylome of MDS HSCs, coupled with the discovery of the TET2-GFI1 epigenetic axis as a suppressor of malignant transformation, marks a seminal contribution to hematological cancer research. By unraveling the intricate epigenetic choreography underpinning MDS initiation, this study paves the way for innovative, targeted therapies that could transform patient outcomes in one of the most challenging hematopoietic malignancies.
Subject of Research: Animals
Article Title: Base-resolution DNA methylome of human MDS hematopoietic stem cells reveals TET2-GFI1 epigenetic axis repressing MDS
News Publication Date: 1-Apr-2026
References: DOI: http://doi.org/10.1007/s44466-026-00034-4
Image Credits: “Human Stem Cells” by NIH-NCATS from Openverse
Keywords: Hematopoietic stem cells, DNA methylation, Epigenetics, Myelodysplastic syndromes, TET2, GFI1, Cancer stem cells, Epigenetic therapy, DNA hypomethylating agents, Stem cell aging, Cancer genetics, Transcriptional regulation
